BEAM vs SHC: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

SHC is the larger of the two ($4.52B market cap): the incumbent the market prices for continued execution (14.87x forward earnings, beta 1.93). BEAM is the smaller challenger ($2.20B), still expected to post a loss next year: more room to run, but more to prove. On the numbers, SHC leads on both counts: faster expected revenue growth (5% vs -32%) and expected profits next year, which BEAM does not have. The case for BEAM rests on its own driver (Risto-cel sickle cell path to filing): if you believe in that, BEAM fits; if you believe in what the numbers show today, SHC does.

BEAM vs SHC: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBEAMSHCWhat it tells you
Market cap$2.20B$4.52BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-4.1114.87Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta2.221.93Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range5% of range41% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.226.17How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how BEAM and SHC affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BEAM and SHC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BEAM and SHC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Beam Therapeutics (BEAM) do?

Beam Therapeutics (NASDAQ: BEAM) develops precision genetic medicines using base editing, a technique it helped invent that rewrites a single letter of DNA without cutting both strands of the double helix, aiming for more precise fixes than first-generation CRISPR. Its pipeline spans risto-cel (formerly BEAM-101) for sickle cell disease, with a biologics license application targeted as early as year-end 2026, plus BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-301 and BEAM-304 for rare liver-mediated genetic diseases. The company also runs collaborations with partners including Pfizer and Eli Lilly, which supply most of its reported revenue through upfront payments and milestones.

Full BEAM guide

What does Sotera Health (SHC) do?

Sotera Health provides the step a medical product has to pass before it can be sold: killing whatever is living on it. Sterigenics, the largest of the three units, runs contract sterilization plants using gamma irradiation, ethylene oxide and electron beam, and has done that work for more than 90 years. Nordion supplies the cobalt-60 that makes gamma sterilization possible, along with the irradiator systems that house it, and the company estimates gamma handles roughly 30% of single-use medical device sterilization worldwide. Nelson Labs sells microbiological and analytical chemistry testing (over 900 distinct tests) plus the regulatory advisory work customers need to validate a sterilization method and defend it to a regulator. Revenue for the twelve months to September 30, 2026 was ~$1.23 billion across 62 facilities and more than 3,000 employees. The customer list is concentrated at the top of the industry: over 40 of the top 50 medical device companies and nine of the ten largest global pharmaceutical companies. More than 90% of both Sterigenics and Nordion revenue in 2025 came from customers on multi-year contracts, so volumes track device production rather than any discretionary spending cycle.

Full SHC guide

BEAM vs SHC: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • BEAM drivers: Risto-cel sickle cell path to filing; In vivo liver franchise.
  • SHC drivers: Contracted volume and repeat pricing; Nordion's cobalt-60 position and the harvest cycle.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Beam is pre-commercial and deeply unprofitable, so it carries the full binary risk of a clinical-stage biotech: a single failed trial, safety signal, or regulatory setback can reset the stock. For SHC, the ethylene oxide tort docket is the dominant, partly quantified risk.

BEAM or SHC: which should you pick?

If the story you believe is BEAM's (Risto-cel sickle cell path to filing), BEAM is the more direct way to own it; if it is SHC's (Contracted volume and repeat pricing), SHC is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BEAM and SHC guides.

BEAM vs SHC: the full fundamentals

BEAM. Beam's revenue is collaboration and milestone income, not product sales, so it is lumpy (about $114 million in the fourth quarter of 2025, under $1 million in each of the second and third quarters of 2026) and not comparable to a profitable company's top line. With no approved therapy and heavy R&D spending, the company runs large net losses funded by its cash pile, and analysts expect a loss of about $4.58 per share for 2026. At about $2.2 billion as of November 20, 2026, the market value is roughly twice the cash balance, while the 13 analysts tracked by Yahoo Finance carry a mean target near $50.

SHC. Roughly 11x enterprise value to EBITDA is a modest price for a business earning around 51% adjusted EBITDA margins on largely contracted revenue from a regulated, hard-to-replicate asset base. The discount is the litigation: Sotera carries no reserve for the ~970 ethylene oxide claims outstanding as of July 31, 2026, so the multiple embeds an unpriced tail, not a known cost. The ~26x trailing GAAP P/E reflects amortization, interest and settlement charges the adjusted figures strip out, and after a ~19% three-month fall and a softer European outlook the forward multiple has come down to ~15x.

Headline figures (approximate, November 2026): BEAM shows market cap ~$2.2B (November 20, 2026), revenue (ttm, collaboration) ~$147M, revenue (q3 2026) ~$0.3M, net loss (q3 2026) ~$134M; SHC shows revenue (ttm) ~$1.23 billion for the twelve months to September 30, 2026, against ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Third-quarter 2026 revenue was ~$324.9 million, up 4.4% in constant currency, after 9.2% growth in the second quarter. Full-year revenue guidance ($1.236 billion to $1.254 billion as of August) was reaffirmed on a constant-currency basis on November 3, 2026; consensus is ~$1.24 billion for 2026 and ~$1.31 billion for 2027., earnings and eps GAAP net income of ~$173.5 million for the twelve months to September 30, 2026, a ~14.1% net margin, against $77.9 million in fiscal 2025 and $44.4 million in fiscal 2024; trailing diluted EPS is ~$0.60. Q3 2026 net income was ~$58.4 million and adjusted EPS of $0.29, up 12%, beat the ~$0.27 consensus, the fifth straight quarter at or above estimates. Consensus adjusted EPS is ~$0.98 for 2026 and ~$1.07 for 2027., segment mix and margins For fiscal 2025, Sterigenics contributed $755.8 million of revenue (65% of the total) at a 54.6% segment margin, Nordion $187.6 million (16%) at 57.3%, and Nelson Labs $220.2 million (19%) at 33.3%. In Q3 2026 Sterigenics grew 8.2% and Nelson Labs 9.2% in constant currency while Nordion fell 12.4% on cobalt harvest timing; Nelson Labs' segment margin was 32.1%. Management expects full-year adjusted EBITDA margin roughly flat, near 51%., cash flow and capital spending Operating cash flow was $111 million in Q3 2026 and $228 million year to date. Capital expenditure guidance for 2026 is $200 million to $225 million, close to 17% of revenue, so Yahoo's trailing free cash flow of ~$146 million is a small fraction of EBITDA. Management expects a meaningful capex step-down after ethylene oxide facility upgrades finish in Q1 2027, toward a $500 million to $600 million free cash flow objective..

The bottom line: BEAM vs SHC

BEAM and SHC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BEAM and SHC exposure against your real portfolio. It is not an investment adviser.

Wondering how BEAM or SHC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Beam Therapeutics

Ask Walnut's AI anything about BEAM and see how it fits what you own.

FAQ

What is the difference between BEAM and SHC?

+

Beam Therapeutics (NASDAQ: BEAM) develops precision genetic medicines using base editing, a technique it helped invent that rewrites a single letter of DNA without cutting both strands of the double helix, aiming for more precise fixes than first-generation CRISPR. Sotera Health provides the step a medical product has to pass before it can be sold: killing whatever is living on it. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BEAM or SHC the better stock?

+

Neither is universally better. SHC is the larger incumbent; BEAM is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BEAM or SHC?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BEAM and SHC?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BEAM vs SHC?

+

BEAM: Beam is pre-commercial and deeply unprofitable, so it carries the full binary risk of a clinical-stage biotech: a single failed trial, safety signal, or regulatory setback can reset the stock. Gene and cell therapies face complex manufacturing, long timelines, and uncertain pricing and reimbursement even after approval. Despite a large cash balance, sustained losses mean future capital raises and shareholder dilution are plausible. The company competes in a crowded gene-editing field, and sector-wide sentiment can pressure the shares regardless of Beam's own progress. There is no guarantee any program reaches the market, and even with positive BEACON data the risto-cel filing still has to clear FDA review and then compete commercially with approved sickle cell gene therapies. The stock's 7% fall after the BEACON announcement shows that positive data alone does not set the price. Litigation is now part of the picture too: Beam's September 2026 trade-secret suits against two biotechs could take years and cost money, with uncertain outcomes. SHC: The ethylene oxide tort docket is the dominant, partly quantified risk. Sterigenics and affiliates have already agreed to pay $408.0 million to settle over 880 Willowbrook, Illinois claims (term sheets January 2023, finalized June 2023), $35 million for 79 Atlanta claims in October 2023, $30.9 million for 97 more Illinois claims in April 2025 and $34.0 million for 129 further Illinois claims in July 2025. A single Cook County jury returned a $358.7 million verdict in 2022, of which $320 million was punitive. As of July 31, 2026 the open inventory was approximately 500 Georgia personal-injury and wrongful-death claims, ~305 Georgia property-devaluation suits, ~150 California claims tied to the Vernon facilities with initial trials scheduled for January and April 2027, and ~15 Illinois cases. The company states that losses in the remaining cases are not probable and carries no reserve for them, so an adverse verdict would land unprovided for. Georgia rulings currently favor the defense, since the trial court excluded plaintiffs' general causation experts and entered summary judgment in March 2026, but those rulings are on appeal, with an appellate decision expected in spring 2027. All Illinois cases have been assigned to one judge and pretrial proceedings are under way. Regulation is the second exposure. The EPA's March 2024 NESHAP rules require permanent total enclosure capture, higher control efficiencies and continuous emissions monitoring at ethylene oxide sterilizers. A July 2025 Clean Air Act proclamation granted Sotera's facilities a two-year exemption, and a January 2026 suit in the District of Columbia seeks to invalidate that exemption and restore the original deadline. Capital expenditure guidance of $200 million to $225 million for 2026, against ~$1.24 billion of consensus revenue, reflects part of that compliance burden and keeps free cash flow far below adjusted EBITDA. A separate FIFRA interim decision issued in January 2025 phases in tighter worker exposure limits over one to ten years. Three smaller items sit behind those. Total debt of ~$2.28 billion against book equity of roughly $0.7 billion (price to book is ~6.2x) leaves limited cushion if volumes stall. The United States has a single industry supplier of ethylene oxide. And Nelson Labs shrank 3.9% in 2025 and grew only 0.9% in constant currency in the first half of 2026 before recovering to 9.2% in the third quarter, when its segment margin fell 199 basis points to 32.1% on business mix, a reminder that the testing unit does not behave like the sterilization ones. Demand and sentiment are the last item. Management said European medical device customers turned less optimistic from the middle of the third quarter into the fourth, and two analysts cut fourth-quarter estimates over the 60 days to mid-November, taking consensus to ~$0.26 of EPS on ~$318 million of revenue, roughly flat year over year. After a run to the $19.85 52-week high, the stock met a JPMorgan downgrade to underweight with a $17 target in October and has since fallen below that level, closing at ~$15.83 on November 20, 2026.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BEAM or SHC; figures are approximate and dated (as of November 2026). Verify current data before investing.